FMP
Avadel Pharmaceuticals plc
AVDL
NASDAQ
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
17.81 USD
-0.01 (-0.05615%)
About
ceo
Mr. Gregory J. Divis Jr.
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
website
https://www.avadel.com
exchange
NASDAQ
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
CIK
0001012477
ISIN
US05337M1045
CUSIP
05337M104
Address
10 Earlsfort Terrace
Phone
353 1 901 5201
Country
IE
Employee
154
IPO Date
Jun 7, 1996
Key Executives
